Effects of allicin supplementation on plasma markers of exercise-induced muscle damage, IL-6 and antioxidant capacity.
To investigate the effects of allicin supplementation on exercise-induced muscle damage (EIMD), interleukin-6 (IL-6), and antioxidative capacity, a double-blinded, placebo-controlled study was conducted in well-trained athletes. Subjects were randomly assigned to an allicin supplementation group (AS group) and a control group, and received either allicin or placebo for 14 days before and 2 days after a downhill treadmill run. Plasma creatine kinase (CK), muscle-specific creatine kinase (CK-MM), lactate dehydrogenase (LDH), IL-6, superoxide dismutase (SOD), total antioxidative capacity (TAC), and perceived muscle soreness were measured pre and post exercise. AS group had significantly lower plasma levels of CK, CK-MM and IL-6, and reduced perceived muscle soreness after exercise, when compared with the control group. AS group also demonstrated a trend toward reducing plasma concentration of LDH after exercise (P = 0.08), although not statistically significant. Allicin supplementation induced a higher value of TAC at rest, and this higher value was maintained 48 h after exercise, however, there was no difference in SOD values after exercise between the two groups. The results suggested that allicin might be a potential agent to reduce EIMD. Further studies concerning anti-inflammatory and anti-oxidative effects of allicin on EIMD are needed.
Su
Quan-Sheng
QS
Chengdu Physical Education University, No.2 Ti-Yuan Road, 610041 Chengdu, China. sqs111@126.com
Tian
Ye
Y
Zhang
Jian-Guo
JG
Zhang
Hui
H
D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000975:Antioxidants / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D002214:Capsules; D003402:Creatine Kinase / Q000097:blood; D052283:Creatine Kinase, MM Form / Q000097:blood; D019587:Dietary Supplements; D004220:Disulfides; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D015444:Exercise; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D010146:Pain / Q000378:metabolism / Q000517:prevention & control; D010147:Pain Measurement; D012420:Running; D013441:Sulfinic Acids / Q000008:administration & dosage*; D013482:Superoxide Dismutase / Q000097:blood; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D015415:Biomarkers; D002214:Capsules; D004220:Disulfides; D015850:Interleukin-6; D013441:Sulfinic Acids; C006452:allicin; D007770:L-Lactate Dehydrogenase; D013482:Superoxide Dismutase; D003402:Creatine Kinase; D052283:Creatine Kinase, MM Form